Normalization of patient-identified plasma biomarkers in SMNΔ7 mice following postnatal SMN restoration

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Arnold, W David ^a   Duque, Sandra ^b   Iyer, Chitra C ^a   Zaworski, Phillip ^c   McGovern, Vicki L ^a   Taylor, Shannon J ^c   Von Herrmann, Katharine M ^d   Kobayashi, Dione T ^d   Chen, Karen S ^d   Kolb, Stephen J ^a   Paushkin, Sergey V ^d   Burghes, Arthur H M ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c PharmOptima   (United States)

^d SMA Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; CADHERIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CHITINASE 3 LIKE 1; DIPEPTIDYL PEPTIDASE IV; FETUIN A; OSTEOPONTIN; PROTEIN AXL; SOMATOMEDIN C; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; TETRANECTIN; UNCLASSIFIED DRUG; VITRONECTIN; SMN1 PROTEIN, MOUSE; SMN2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BRAIN LEVEL; CONTROLLED STUDY; GENE; HISTOPATHOLOGY; LIVER LEVEL; MOLECULAR DYNAMICS; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PERINATAL PERIOD; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; QUADRICEPS FEMORIS MUSCLE; SMN1 GENE; SMN2 GENE; SPINAL CORD; SPINAL MUSCULAR ATROPHY; ANIMAL; BRAIN; CLINICAL TRIAL (TOPIC); DISEASE MODEL; GENE EXPRESSION REGULATION; GENETIC COMPLEMENTATION; GENETICS; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LIVER; METABOLISM; MOTONEURON; NEWBORN; PATHOLOGY; SKELETAL MUSCLE; TRANSGENIC MOUSE;

ANIMALS; ANIMALS, NEWBORN; BIOMARKERS; BRAIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC COMPLEMENTATION TEST; HUMANS; INJECTIONS, INTRAVENTRICULAR; LIVER; MICE; MICE, TRANSGENIC; MOTOR NEURONS; MUSCLE, SKELETAL; MUSCULAR ATROPHY, SPINAL; OLIGONUCLEOTIDES, ANTISENSE; SPINAL CORD; SURVIVAL OF MOTOR NEURON 1 PROTEIN; SURVIVAL OF MOTOR NEURON 2 PROTEIN;

EID: 84999850002     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0167077     Document Type: Article

References (64)

1. Roberts DF, Chavez J, Court SD. The genetic component in child mortality. Arch Dis Child. 1970; 45 (239):33-8. PMID: 4245389
2. Crawford TO, Pardo CA. The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis. 1996; 3 (2):97-110. Epub 1996/04/01. doi: 10.1006/nbdi.1996.0010 PMID: 9173917
3. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995; 80(1):155-65. Epub 1995/01/13. PMID: 7813012
4. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997; 16(3):265-9. Epub 1997/07/01. doi: 10.1038/ng0797-265 PMID: 9207792
5. Coovert DD, Le TT, McAndrew PE, Strasswimmer J, Crawford TO, Mendell JR, et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997; 6(8):1205-14. Epub 1997/08/01. PMID: 9259265
6. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999; 96(11):6307-11. Epub 1999/05/26. PMID: 10339583
7. Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AH, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999; 8(7):1177-83. Epub 1999/06/17. PMID: 10369862
8. Gennarelli M, Lucarelli M, Capon F, Pizzuti A, Merlini L, Angelini C, et al. Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem Biophys Res Commun. 1995; 213(1):342-8. Epub 1995/08/04. doi: 10.1006/bbrc.1995.2135 PMID: 7639755
9. Cartegni L, Krainer AR. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet. 2002; 30(4):377-84. Epub 2002/04/02. doi: 10.1038/ng854 PMID: 11925564
10. Kashima T, Manley JL. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet. 2003; 34(4):460-3. Epub 2003/07/02. doi: 10.1038/ng1207 PMID: 12833158
11. Lorson CL, Strasswimmer J, Yao JM, Baleja JD, Hahnen E, Wirth B, et al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet. 1998; 19(1):63-6. Epub 1998/05/20. doi: 10.1038/ng0598-63 PMID: 9590291
12. Lorson CL, Androphy EJ. An exonic enhancer is required for inclusion of an essential exon in the SMAdetermining gene SMN. Hum Mol Genet. 2000; 9(2):259-65. Epub 1999/12/23. PMID: 10607836
13. Burnett BG, Munoz E, Tandon A, Kwon DY, Sumner CJ, Fischbeck KH. Regulation of SMN protein stability. Molecular and cellular biology. 2009; 29(5):1107-15. Epub 2008/12/24. doi: 10.1128/MCB. 01262-08 PMID: 19103745
14. Munsat TL, Davies KE. International SMA consortium meeting. (26-28 June 1992, Bonn, Germany). Neuromuscular disorders: NMD. 1992; 2(5-6):423-8. Epub 1992/01/01. PMID: 1300191
15. Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995; 52 (5):518-23. PMID: 7733848
16. McAndrew PE, Parsons DW, Simard LR, Rochette C, Ray PN, Mendell JR, et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet. 1997; 60(6):1411-22. Epub 1997/06/01. doi: 10.1086/515465 PMID: 9199562
17. Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genetics in medicine: official journal of the American College of Medical Genetics. 2002; 4(1):20-6. Epub 2002/02/13.
18. Elsheikh B, Prior T, Zhang X, Miller R, Kolb SJ, Moore D, et al. An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy. Muscle & nerve. 2009; 40(4):652-6. Epub 2009/09/18.
19. Wirth B, Herz M, Wetter A, Moskau S, Hahnen E, Rudnik-Schoneborn S, et al. Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet. 1999; 64(5):1340-56. Epub 1999/04/17. doi: 10.1086/302369 PMID: 10205265
20. Campbell L, Potter A, Ignatius J, Dubowitz V, Davies K. Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype. Am J Hum Genet. 1997; 61(1):40-50. Epub 1997/07/01. doi: 10.1086/513886 PMID: 9245983
21. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002; 70(2):358-68. Epub 2002/01/16. doi: 10.1086/338627 PMID: 11791208
22. Prior TW, Krainer AR, Hua Y, Swoboda KJ, Snyder PC, Bridgeman SJ, et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009; 85(3):408-13. Epub 2009/09/01. doi: 10.1016/j.ajhg.2009.08.002 PMID: 19716110
23. Vezain M, Saugier-Veber P, Goina E, Touraine R, Manel V, Toutain A, et al. A rare SMN2 variant in a previously unrecognized composite splicing regulatory element induces exon 7 inclusion and reduces the clinical severity of spinal muscular atrophy. Human mutation. 2010; 31(1):E1110-25. Epub 2009/12/03. doi: 10.1002/humu.21173 PMID: 19953646
24. Bernal S, Alias L, Barcelo MJ, Also-Rallo E, Martinez-Hernandez R, Gamez J, et al. The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor. Journal of medical genetics. 2010; 47(9):640-2. Epub 2010/06/26. doi: 10.1136/jmg.2010.079004 PMID: 20577007
25. Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nature Reviews Neuroscience. 2009; 10(8):597-609.
26. Arnold WD, Burghes AH. Spinal muscular atrophy: The development and implementation of potential treatments. Ann Neurol. 2013. Epub 2013/08/14.
27. Monani UR, Sendtner M, Coovert DD, Parsons DW, Andreassi C, Le TT, et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn-/-mice and results in a mouse with spinal muscular atrophy. Human Molecular Genetics. 2000; 9(3):333-9. PMID: 10655541
28. Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, et al. A mouse model for spinal muscular atrophy. Nat Genet. 2000; 24(1):66-70. Epub 1999/12/30. doi: 10.1038/71709 PMID: 10615130
29. Le TT, Pham LT, Butchbach MER, Zhang HL, Monani UR, Coovert DD, et al. SMNΔ7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Human Molecular Genetics. 2005; 14(6):845-57. doi: 10.1093/hmg/ddi078 PMID: 15703193
30. Naryshkin NA, Weetall M, Dakka A, Narasimhan J, Zhao X, Feng Z, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science (New York, NY). 2014; 345(6197):688-93. Epub 2014/08/12.
31. Palacino J, Swalley SE, Song C, Cheung AK, Shu L, Zhang X, et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol. 2015; 11(7):511-7. http://www.nature.com/nchembio/journal/v11/n7/abs/nchembio.1837.html#supplementary-information. doi: 10.1038/nchembio.1837 PMID: 26030728
32. Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek LM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Science translational medicine. 2011; 3(72):72ra18. Epub 2011/03/04. doi: 10.1126/scitranslmed.3001777 PMID: 21368223
33. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature. 2011; 478(7367):123-6. doi: 10.1038/nature10485 PMID: 21979052
34. Porensky PN, Mitrpant C, McGovern VL, Bevan AK, Foust KD, Kaspar BK, et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet. 2012; 21 (7):1625-38. Epub 2011/12/22. doi: 10.1093/hmg/ddr600 PMID: 22186025
35. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010; 28 (3):271-4. Epub 2010/03/02. doi: 10.1038/nbt.1610 PMID: 20190738
36. Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ, et al. Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy. Science Translational Medicine. 2010; 2(35):35ra42. doi: 10.1126/scitranslmed.3000830 PMID: 20538619
37. Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet. 2011; 20 (4):681-93. Epub 2010/12/02. doi: 10.1093/hmg/ddq514 PMID: 21118896
38. Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, O'Riordan CR, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. The Journal of clinical investigation. 2010; 120(4):1253-64. Epub 2010/03/18. doi: 10.1172/JCI41615 PMID: 20234094
39. Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle & nerve. 2015; 51(2):157-67. Epub 2014/10/28.
40. Duque SI, Arnold WD, Odermatt P, Li X, Porensky PN, Schmelzer L, et al. A large animal model of spinal muscular atrophy and correction of phenotype. Ann Neurol. 2015; 77(3):399-414. Epub 2014/12/18. doi: 10.1002/ana.24332 PMID: 25516063
41. Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016; 86(10):890-7. Epub 2016/02/13. doi: 10.1212/WNL.0000000000002445 PMID: 26865511
42. Tiziano FD, Neri G, Brahe C. Biomarkers in rare disorders: the experience with spinal muscular atrophy. International journal of molecular sciences. 2010; 12(1):24-38. Epub 2011/02/23. doi: 10.3390/ijms12010024 PMID: 21339974
43. Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Baseline results of the Neuro NEXT spinal muscular atrophy infant biomarker study. Annals of clinical and translational neurology. 2016; 3(2):132-45. Epub 2016/02/24. doi: 10.1002/acn3.283 PMID: 26900585
44. Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, et al. Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function. Annals of Neurology. 2005; 57 (5):704-12. doi: 10.1002/ana.20473 PMID: 15852397
45. Ng KW, Connolly AM, Zaidman CM. Quantitative muscle ultrasound measures rapid declines over time in children with SMA type 1. Journal of the neurological sciences. 2015; 358(1-2):178-82. Epub 2015/10/04. doi: 10.1016/j.jns.2015.08.1532 PMID: 26432577
46. Rutkove SB, Geisbush TR, Mijailovic A, Shklyar I, Pasternak A, Visyak N, et al. Cross-sectional evaluation of electrical impedance myography and quantitative ultrasound for the assessment of Duchenne muscular dystrophy in a clinical trial setting. Pediatric neurology. 2014; 51(1):88-92. doi: 10.1016/j. pediatrneurol.2014.02.015 PMID: 24814059
47. Lewelt A, Krosschell KJ, Scott C, Sakonju A, Kissel JT, Crawford TO, et al. Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle & nerve. 2010; 42 (5):703-8.
48. Bromberg MB, Swoboda KJ. Motor unit number estimation in infants and children with spinal muscular atrophy. Muscle & nerve. 2002; 25(3):445-7.
49. Kaufmann P, McDermott MP, Darras BT, Finkel R, Kang P, Oskoui M, et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol. 2011; 68(6):779-86. Epub 2011/02/16. doi: 10.1001/archneurol.2010.373 PMID: 21320981
50. Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, Kang PB, et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012; 79(18):1889-97. Epub 2012/10/19. doi: 10.1212/WNL.0b013e318271f7e4 PMID: 23077013
51. Arnold W, McGovern VL, Sanchez B, Li J, Corlett KM, Kolb SJ, et al. The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy. Neurobiol Dis. 2016; 87:116-23. Epub 2016/01/07. doi: 10.1016/j.nbd.2015.12.014 PMID: 26733414
52. Arnold WD, Porensky PN, McGovern VL, Iyer C, Duque S, Li X, et al. Electrophysiological Biomarkers in Spinal Muscular Atrophy: Preclinical Proof of Concept. Annals of clinical and translational neurology. 2014; 1(1):34-44. doi: 10.1002/acn3.23 PMID: 24511555
53. Bogdanik LP, Osborne MA, Davis C, Martin WP, Austin A, Rigo F, et al. Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy. Proc Natl Acad Sci U S A. 2015; 112(43):E5863-72. Epub 2015/10/16. doi: 10.1073/pnas.1509758112 PMID: 26460027
54. Finkel RS, Crawford TO, Swoboda KJ, Kaufmann P, Juhasz P, Li X, et al. Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study. PLoS ONE. 2012; 7(4):e35462. Epub 2012/05/05. doi: 10.1371/journal.pone.0035462 PMID: 22558154
55. Kobayashi DT, Shi J, Stephen L, Ballard KL, Dewey R, Mapes J, et al. SMA-MAP: a plasma protein panel for spinal muscular atrophy. PloS one. 2013; 8(4):e60113. Epub 2013/04/09. doi: 10.1371/journal.pone.0060113 PMID: 23565191
56. McGovern VL, Iyer CC, Arnold WD, Gombash SE, Zaworski PG, Blatnik AJ 3rd, et al. SMN expression is required in motor neurons to rescue electrophysiological deficits in the SMNDelta7 mouse model of SMA. Hum Mol Genet. 2015. Epub 2015/07/25.
57. Arnold WD, Sheth KA, Wier CG, Kissel JT, Burghes AH, Kolb SJ. Electrophysiological Motor Unit Number Estimation (MUNE) Measuring Compound Muscle Action Potential (CMAP) in Mouse Hindlimb Muscles. Journal of visualized experiments: JoVE. 2015;(103:). Epub 2015/10/06.
58. Zaworski P, von Herrmann KM, Taylor S, Sunshine SS, McCarthy K, Risher N, et al. SMN Protein Can Be Reliably Measured in Whole Blood with an Electrochemiluminescence (ECL) Immunoassay: Implications for Clinical Trials. PLoS One. 2016; 11(3):e0150640. Epub 2016/03/10. doi: 10.1371/journal. pone.0150640 PMID: 26953792
59. Arnold WD, Porensky PN, McGovern VL, Iyer CC, Duque S, Li X, et al. Electrophysiological Biomarkers in Spinal Muscular Atrophy: Preclinical Proof of Concept. Annals of clinical and translational neurology. 2014; 1(1):34-44. doi: 10.1002/acn3.23 PMID: 24511555
60. Chen Y, Han H, Yan X, Ding F, Su X, Wang H, et al. Tetranectin as a Potential Biomarker for Stable Coronary Artery Disease. Scientific reports. 2015; 5:17632. Epub 2015/12/02. doi: 10.1038/srep17632 PMID: 26621497
61. Rohrborn D, Wronkowitz N, Eckel J. DPP4 in Diabetes. Frontiers in immunology. 2015; 6:386. Epub 2015/08/19. doi: 10.3389/fimmu.2015.00386 PMID: 26284071
62. Bowerman M, Swoboda KJ, Michalski JP, Wang GS, Reeks C, Beauvais A, et al. Glucose metabolism and pancreatic defects in spinal muscular atrophy. Annals of neurology. 2012; 72(2):256-68. Epub 2012/08/29. doi: 10.1002/ana.23582 PMID: 22926856
63. Harris VK, Donelan N, Yan QJ, Clark K, Touray A, Rammal M, et al. Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2013; 19 (11):1462-72. Epub 2013/02/27.
64. Choi ST, Kim JH, Kang E-J, Lee S-W, Park M-C, Park Y-B, et al. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology. 2008; 47(12):1775-9. doi: 10.1093/rheumatology/ken385 PMID: 18854347